Current Report Filing (8-k)
15 November 2021 - 08:34PM
Edgar (US Regulatory)
0001477845 false 0001477845 2021-11-15
2021-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 15, 2021
ANNOVIS BIO, INC.
(Exact Name of Registrant as Specified in
Charter)
|
|
|
|
|
Delaware |
|
001-39202 |
|
26-2540421 |
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
1055 Westlakes Drive,
Suite 300
Berwyn,
PA
19312
(Address of Principal Executive Offices, and Zip Code)
(610)
727-3913
Registrant’s Telephone Number, Including Area Code
Not
Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which
registered |
Common Stock, par value $0.0001 per share |
ANVS |
NYSE American |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General
Instruction A.2. below):
|
¨ |
Written communication
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
¨ |
Pre-commencement
communication pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement
communication pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR §240.12b-2).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 3.01 |
Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing. |
On November 15, 2021, Annovis Bio, Inc. (the “Company”) announced
that the New York Stock Exchange (“NYSE”) had approved the transfer
of listing of the common stock, $0.0001 par value per share (the
“Common Stock”) of the Company from the NYSE American to the NYSE
and that, effective November 18, 2021, the Company’s Common Stock
will cease trading on the NYSE American and will commence trading
on the NYSE under the symbol “ANVS” and until the close of trading on
November 17, 2021, the Common Stock will continue to trade on the
NYSE American under the symbol “ANVS.”
Item 7.01 |
Regulation FD Disclosure. |
On November 15, 2021, the Company issued a press release announcing
the transfer of listing from the NYSE American to the NYSE. A copy
of the Press Release is attached to this Current Report on Form 8-K
as Exhibit 99.1.
The information in this Item 7.01, Item 9.01 and Exhibit 99.1
attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, or otherwise subject to
the liability of such section, nor shall it be deemed incorporated
by reference in any filing of the Company under the Securities Act
of 1933 or the Securities Exchange Act of 1934, regardless of any
general incorporation language in such filing, unless expressly
incorporated by specific reference in such filing.
Item 9.01 |
|
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ANNOVIS BIO,
INC. |
|
|
|
Date: November 15, 2021 |
By: |
/s/ Jeffrey McGroarty |
|
|
Name: Jeffrey McGroarty |
|
|
Title: Chief Financial Officer |
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Apr 2022 bis Mai 2022
Annovis Bio (NYSE:ANVS)
Historical Stock Chart
Von Mai 2021 bis Mai 2022